|
|
 |
|
Viewing report
|
|
|
|
Company Financials: Dendreon Corporation
Datamonitor, Jan 2010
The Company Financials offers insights into the financial performance of the company over last five years for about 1000 leading global companies. The datapack covers wealth of financial information relating to income statement, balance sheet, and cash flow statements. .
Scope
- Contains five years data on income statement, balance sheet, cash flows and other financials in the reported currency and its US Dollar translation
- Provides key ratios
- Includes information on revenue distribution by business segments and geographies
Highlights of this title
Dendreon Corporation (Dendreon) is a biotechnology company engaged in discovering, developing and commercialization of novel therapeutics to fight cancer.
Dendreon's lead Active Cellular Immunotherapy ACI product candidate known as Provenge (sipuleucel-T) is in late-stage development for the treatment of men with metastatic, androgen-independent prostate cancer.
Key reasons to purchase this title
- Access important financial information and analysis on the company in a single datapack
- Understand the financial evolution of the five company over the last years
- Build the periodic assessment of the company's performance for five year adjusted financial data along with key ratios and market capitalization
Customers who bought this item also bought
Company Financials: Mannkind Corporation
Company Financials: CuraGen Corporation
Company Financials: Allos Therapeutics, Inc.
Company Financials: Arqule, Inc.
Company Financials: Genzyme Corporation
Company Financials: Amgen, Inc.
Company Financials: Genta Incorporated
Company Financials: Exelixis
Company Financials: Biocryst Pharmaceuticals
Company Financials: GTx, Inc.
|
|
|
|
